PEBP1 and hepatocellular carcinoma: RKIP has been identified as a member of a novel class of metastasis suppressors, with evidence from prostate cancer, breast cancer, malignant melanoma, insulinoma, colorectal cancer, hepatocellular carcinoma and esophageal cancer (14,24).